Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: hiv + treatment + web  Related to the article below (Last Update: 8/4/2008)

New HIV/AIDS Guidelines Suggest Earlier Treatment
U.S. News & World Report, DC - Aug 3, 2008
HIV-infected patients with abdominal obesity and growth hormone deficiency related to their treatment regimens who received low-dose growth hormone showed ...

BBC News
The 411 on Sexual Health
Dallas Morning News, TX -
The Centers for Disease Control and Prevention (CDC) announced in August 2008 that the number of Americans infected with HIV is much higher than previously ...
US HIV infection rate 40% higher than estimated PinkNews.co.uk
all 1,230 news articles »
Marchers Demand AIDS Testing and Treatment as Mexico City AIDS ...
MarketWatch - Aug 3, 2008
In a spirited march that began at Plaza de la Revolucion and progressed to the Zocalo Plaza advocates called for increased access to HIV testing and ...
Africa: Aids Updates and Analysis
AllAfrica.com, Washington - Aug 3, 2008
Brazil has been cited as a great success story for developing strong HIV treatment and prevention programs as well as general public health programs. ...

Voice of America
International AIDS Conference Mobilizes Online
eMaxHealth.com, NC -
The NGOs, doctors and AIDS organizations are going online to talk about AIDS and find prevention and treatment methods. The human rights platforms are ...
AIDS experts urge Latin America to act now, avoid becoming next Africa Tico Times
International AIDS Conference Unites Many To Find HIV Vaccine ChattahBox
International AIDS Conference Aims To Find HIV Vaccine dBTechno
BuaNews Online (press release)
all 346 news articles »
Monogram Biosciences Launches First Resistance Assay for HIV ...
CNNMoney.com (press release) -
In Merck?s phase III BENCHMRK trials, Monogram?s PhenoSenseGT was used to select optimized drug regimens in the placebo and Isentress-containing treatment ...MGRM
Human Rights Groups Petition Iran for Release of HIV/AIDS Doctors
PR Web (press release), WA -
The doctors, who are brothers, are active in HIV/AIDS education, prevention and treatment in Iran. According to international news reports, Iranian security ...
New 'From-the-Ground' Report Reformulates Simplistic Argument ...
FOXBusiness - Jul 30, 2008
Brazil has been cited as a great success story for developing strong HIV treatment and prevention programs as well as general public health programs. ...
'Project Runway' designer drops in on NO
The Times-Picayune - NOLA.com, LA -
By Susan Langenhennig The hunky, 39-year-old HIV-positive fashion designer was a fan favorite on last season's "Project Runway" when he had to leave the ...
Sustainability of AIDS funding needs a checkup
Business Day, South Africa - Jul 31, 2008
ON WEDNESDAY, George Bush signed into the law the Tom Lantos and Henry J Hyde US Global Leadership Against HIV/AIDS, Tuberculosis and Malaria ...
House ready to OK $48B in global AIDS fight WJLA
google news commentComment by Dr. Paul Zeitz Executive Director, Global AIDS Alliance
all 1,193 news articles »
Source: Google News

HIV Treatment Failure: Testing for HIV Resistance in Clinical Practice -
L Perrin, A Telenti - Science, 1998 - sciencemag.org
... or possibly that you are using a browser that does not support current Web standards. ...
HIV Treatment Failure: Testing for HIV Resistance in Clinical Practice. ...

An information system and medical record to support HIV treatment in rural Haiti -
HSF Fraser, D Jazayeri, P Nevil, Y Karacaoglu, PE … - BMJ: British Medical Journal, 2004 - pubmedcentral.nih.gov
... systems, is considered a barrier to successful HIV treatment programmes in resource
poor areas. The authors describe how they set up a web based medical record ...

Treatment for Adult HIV Infection 2004 Recommendations of the International AIDS Society-USA Panel -
PG Yeni, SM Hammer, MS Hirsch, MS Saag, M … - JAMA, 2004 - Am Med Assoc
... ABSTRACT, Context Substantial changes in the field of human immunodeficiency virus
(HIV) treatment have occurred in the last 2 years, prompting revision of the ...

… and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment … -
JK Wong, HF Gunthard, DV Havlir, ZQ Zhang, AT … - Proceedings of the National Academy of Sciences, 1997 - National Acad Sciences
... Home page, Proc. Natl. Acad. Sci. USA Home page DV Havlir Structured intermittent
treatment for HIV disease: Necessary concession or premature compromise? ...

Antiretroviral Treatment for Adult HIV Infection in 2002 Updated Recommendations of the … -
PG Yeni, SM Hammer, CCJ Carpenter, DA Cooper, MA … - JAMA, 2002 - Am Med Assoc
... CLINICIAN'S CORNER Antiretroviral Treatment for Adult HIV Infection in
2002 ... Rationale for Treatment in Established HIV Infection. ...

Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web … -
GM Lucas - Journal of Antimicrobial Chemotherapy, 2005 - Br Soc Antimicrob Chemo
... viral fitness and HIV disease progression: a tangled web is woven. ... The clinical goals
of HIV treatment are optimally accomplished through consistent high-level ...

[CITATION] … STUDY OF 3 PROTEASE INHIBITOR-SPARING ANTIRETROVIRAL REGIMENS FOR THE INITIAL TREATMENT OF HIV …
A Ther - Antivir Ther, 2003

[CITATION] Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel -
SM Hammer, MS Saag, M Schechter, JSG Montaner, RT … - JAMA: The Journal of the American Medical Association, 2006 - JAMA
You are seeing this message because your Web browser does not support basic Web
standards. ... CLINICIAN'S CORNER Treatment for Adult HIV Infection ...

… PILOT STUDY EVALUATING THE EFFICACY OF ABACAVIR, LAMIVUDINE AND TENOFOVIR IN THE TREATMENT NAIVE HIV …
A Ther - Antivir Ther, 2003 - gateway.nlm.nih.gov
... CONCLUSION: Although preliminary, these results raise the concern about potency
and efficacy of this regimen administered once-daily in HIV treatment naive pts ...

… responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a …
J Jemsek, P Hutcherson, E Harper - 11th Conference on Retroviruses and Opportunistic Infections …, 2004 - gateway.nlm.nih.gov
... Poor Virologic Responses and Early Emergence of Resistance in Treatment Naive,
HIV-infected Patients Receiving a Once Daily Triple Nucleoside Regimen of ...

Source: Google Scholar
 
 

Fuzeon plus an active PI provides maximal HIV suppression in treatment-experienced patients

 
 
Patients previously treated with three classes of antiretrovirals can achieve maximal viral suppression when starting a regimen of Enfuvirtide ( Fuzeon ) in combination with an active boosted protease inhibitor ( PI ) and other anti-HIV drugs.

New study data were presented at the 12th annual Conference on Retroviruses and Opportunistic Infections ( CROI ).

These new studies add to the growing body of evidence that support a powerful treatment strategy for treatment-experienced patients - building upon findings from the Fuzeon pivotal trials, TORO-1 and TORO-2.

" The goal of HIV treatment is to achieve maximum suppression of the virus - for both patients who are starting an antiretroviral regimen for the first time, and those who are treatment-experienced," said Joseph Eron, Jr., at the University of North Carolina, Chapel Hill. " The data presented at CROI are encouraging because they show that this goal is attainable in triple-class experienced patients. Multiple independent studies are showing that the majority of triple-class experienced HIV-positive patients achieve maximal response when an active PI-containing regimen is paired with Fuzeon. "

Investigators reported results of a 24-week phase IIB study of an investigational boosted protease inhibitor, TMC-114/Ritonavir, in triple-class experienced patients.
Of those who received Fuzeon and TMC-114/Ritonavir for the first time, two-thirds ( 67 percent; 18/27 ) achieved undetectable levels of HIV at 24 weeks ( defined as less than 50 copies/mL of HIV in the blood ) compared to one-third ( 37 percent; 10/27 ) of patients who received TMC-114/Ritonavir without Fuzeon as part of their background regimen. Almost half ( 47 percent ) of patients in the trial received Fuzeon.

Integrated results of the phase III RESIST trials of another investigational boosted protease inhibitor, Tipranavir, in triple-class experienced patients were also presented at CROI. In the trial, the greatest treatment response was seen in patients treated with Fuzeon and Tipranavir/Ritonavir, along with other anti-HIV drugs.
Despite extensive prior treatment and resistance to multiple drugs, more than two-thirds ( 70 percent ) of study participants using Fuzeon and Tipranavir/Ritonavir for the first time in their regimens achieved a treatment response ( defined as at least a 1 log drop in HIV levels from baseline ) after 24 weeks of therapy.

Fuzeon is the first and only fusion inhibitor for the treatment of HIV. Unlike other HIV drugs that work after HIV has entered the human immune cell, Fuzeon works outside the CD4 cell, blocking HIV from entering the cell. For this reason, Fuzeon is effective in treatment-experienced patients who have developed resistance to other anti-HIV drugs, though patients may still develop resistance to Fuzeon.

Injection site reactions ( ISRs ) are the most common adverse events associated with Rnfuvirtide.
ISRs occurred in 98% of patients studied and 4% discontinued Enfuvirtide due to ISRs.
Signs/symptoms may include pain and discomfort, hardened skin, redness, bumps, itching and swelling. Eleven percent of patients had local reactions that required analgesics or limited usual activities.

An increased rate of bacterial pneumonia was observed in subjects treated with Enfuvirtide in the Phase III clinical trials compared to the control arm. It is unclear if the increased incidence of pneumonia is related to Enfuvirtide use. Patients with HIV infection should be carefully monitored for signs and symptoms of pneumonia. Risk factors for pneumonia included low initial CD4 cell count, high initial viral load, intravenous drug use, smoking and a prior history of lung disease.

Systemic hypersensitivity reactions have been associated with Enfuvirtide therapy and may recur on rechallenge. Hypersensitivity reactions have included individually and in combination: rash, fever, nausea and vomiting, chills, rigors, hypotension and elevated serum liver transaminases. Other adverse events that may be immune mediated and have been reported in subjects receiving Enfuvirtide include primary immune complex reaction, respiratory distress, glomerulonephritis and Guillain-Barre syndrome.

The events most frequently reported in patients receiving Enfuvirtide plus an optimized background regimen were diarrhea ( 32% ), nausea ( 23% ) and fatigue ( 20% ). These events were seen at a lower incidence in patients taking a Enfuvirtide-based regimen compared to those receiving an optimized background regimen without Enfuvirtide when taking into account the uneven number of patients in each arm and the length of time they are in that arm. As measured in number per 100 patient-years, the incidence was: diarrhea ( 38 per 100 patient-years in subjects receiving Enfuvirtide-based regimens vs. 73 per 100 patient-years in patients who did not receive Enfuvirtide ), nausea ( 27 vs. 50, respectively ) and fatigue ( 24 vs. 38, respectively ).

Source: Trimeris, 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; Nedws9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page